1AD
vs
S
S&P/ASX 300
1AD
Over the past 12 months, 1AD has underperformed S&P/ASX 300, delivering a return of -76% compared to the S&P/ASX 300's +6% growth.
Stocks Performance
1AD vs S&P/ASX 300
Performance Gap
1AD vs S&P/ASX 300
Performance By Year
1AD vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Adalta Ltd
Glance View
AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The company is headquartered in Melbourne, Victoria. The company went IPO on 2016-08-22. The firm is focused on using its technology platform to generate protein therapeutics, known as i-bodies, for treating a range of human diseases. The Company’s lead candidate AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target. The i-body has also demonstrated its usefulness in treating fibrosis of the eye and is being pursued as an additional opportunity for the treatment of age-related macular degeneration (wet-AMD). The i-body is identified to have affinity and specificity with a drug target of interest, its effectiveness is evaluated in cell-based assays (in vitro) and in animal experiments (in vivo).